Get started
Author

Vamsidhar Velcheti

Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
2015 · Kurt A. Schalper, Jason Brown, et al. · JNCI Journal of the National Cancer Institute · 417
Rational design of anti-GITR-based combination immunotherapy
2019 · Roberta Zappasodi, Cynthia Sirard, et al. · Nature Medicine · 228
Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
2015 · Maria Vassilakopoulou, Margaritis Avgeris, et al. · Clinical Cancer Research · 213
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
2019 · Daniel Carvajal-Hausdorf, Mehmet Altan, et al. · Journal for ImmunoTherapy of Cancer · 209
PDF
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
2018 · Kim Margolin, Chihiro Morishima, et al. · Clinical Cancer Research · 208
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
2019 · Anish Thomas, Rasa Vilimas, et al. · Journal of Thoracic Oncology · 185
PDF
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
2022 · Salman R. Punekar, Elaine Shum, et al. · Frontiers in Oncology · 85
PDF
Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
2021 · Vamsidhar Velcheti, Xiaohan Hu, et al. · Scientific Reports · 71
PDF
Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States
2021 · P. Jain, J. Gutierrez Bugarin, et al. · ESMO Open · 68
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
2018 · Vamsidhar Velcheti, Pallavi D. Patwardhan, et al. · PLoS ONE · 67
PDF
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
2017 · Daniel E. Carvajal-Hausdorf, Nikita Mani, et al. · Journal for ImmunoTherapy of Cancer · 49
PDF
Outcomes of First-Line Pembrolizumab Monotherapy for PD-L1-Positive (TPS ≥50%) Metastatic NSCLC at US Oncology Practices
2019 · Vamsidhar Velcheti, Sheenu Chandwani, et al. · Immunotherapy · 42
First-Line Pembrolizumab Monotherapy for Metastatic Pd-L1-Positive Nsclc: creal-World Analysis of Time on Treatment
2019 · Vamsidhar Velcheti, Sheenu Chandwani, et al. · Immunotherapy · 38
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
2024 · Ulka N Vaishampayan, Jameel Muzaffar, et al. · Journal for ImmunoTherapy of Cancer · 35
PDF
Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
2022 · Vamsidhar Velcheti, Xiaohan Hu, et al. · Frontiers in Oncology · 34
PDF
Insulin-Like Growth Factor and Lung Cancer
2006 · Vamsidhar Velcheti, Ramaswamy Govindan · Journal of Thoracic Oncology · 30
PDF
Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT)
2023 · C. Gridelli, S. Peters, et al. · ESMO Open · 28
Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
2022 · Stephen V. Liu, Xiaohan Hu, et al. · Frontiers in Oncology · 25
PDF
Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
2022 · Vamsidhar Velcheti, Xiaohan Hu, et al. · Cancers · 25
PDF
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC
2024 · Vamsidhar Velcheti, Pragya Rai, et al. · Clinical Lung Cancer · 24
PDF
LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study
2024 · N. Girard, M. Burotto, et al. · Annals of Oncology · 22
PDF
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab
2025 · Zofia Piotrowska, Antonio Passaro, et al. · Journal of Clinical Oncology · 20
Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung Cancer: A Comprehensive Review of Current Trials, Guidelines and Future Directions
2024 · Tulika Ranjan, Vivek Podder, et al. · Cancers · 19
PDF
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
Real-World Treatment Patterns and Outcomes in PD-L1-Positive Non-Small Cell Lung Cancer
2021 · Xinke Zhang, Richard W DeClue, et al. · Immunotherapy · 16
Works count: 85
Citation count: 2,255
H-index: 21
I10-index: 27
Year
Topic
Type